AGIO Hits 52-Week Low Amid Trial Setbacks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 27 2025
0mins
Should l Buy AGIO?
Source: SeekingAlpha
Shares of Agios Pharmaceuticals (AGIO.O) plummeted approximately 45% in premarket trading today, marking a new 52-week low for the stock. The significant decline follows mixed results from the late-stage RISE UP trial of mitapivat for sickle cell disease, where the primary endpoint for hemoglobin response was met, but the treatment failed to demonstrate a meaningful reduction in pain crises. Furthermore, serious adverse events were reported in both the treatment and placebo groups, raising concerns among investors. Looking ahead, Agios plans to engage with the U.S. FDA in early 2026 to discuss a marketing application for mitapivat, while also aiming to streamline expenses to facilitate the potential launch of Pyrukynd for thalassemia.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGIO
Wall Street analysts forecast AGIO stock price to rise
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 33.830
Low
25.00
Averages
36.14
High
62.00
Current: 33.830
Low
25.00
Averages
36.14
High
62.00
About AGIO
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Agios Seeks Accelerated Approval for Mitapivat in Sickle Cell Disease
- FDA Review Progress: Agios has submitted a proposal for a confirmatory clinical trial to the FDA for Mitapivat, aimed at supporting its accelerated approval in sickle cell disease, indicating the company's proactive efforts to meet patient needs.
- Clinical Trial Results: The RISE UP Phase 3 trial demonstrated that Mitapivat significantly improved hemoglobin levels compared to placebo, although the annualized rate of pain crises did not reach statistical significance, reflecting the drug's potential clinical value.
- Future Plans: The company plans to submit a supplemental New Drug Application (sNDA) for Mitapivat in the coming months and is actively working with the FDA to align on the confirmatory trial, showcasing its strong commitment to expedited market entry.
- Market Impact: Sickle cell disease is a serious inherited blood disorder, and the successful launch of Mitapivat could provide new treatment options for patients, potentially significantly improving their quality of life and enhancing Agios's market position.
See More
Agios Pharmaceuticals Under Investigation Following Phase 3 Trial Results, Stock Plummets
- Investigation Launched: Levi & Korsinsky has initiated an investigation into Agios Pharmaceuticals, Inc. regarding potential violations of federal securities laws, indicating serious concerns about the company's compliance practices.
- Clinical Trial Results: On November 19, 2025, Agios reported that its RISE UP Phase 3 trial met one primary endpoint but failed to show statistically significant improvement in annualized pain crises, highlighting limitations in treatment efficacy.
- Stock Price Reaction: Following the trial results, Agios' stock plummeted by $22.33 to open at $23.16, reflecting a significant decline in market confidence regarding the company's future prospects, which may impact its ability to raise capital.
- Investor Impact: The investigation and stock drop could erode investor trust in Agios, further affecting its market performance and shareholder value, underscoring the company's inadequate risk management in clinical development.
See More
Health Care Stocks Rise 2% Boosting Market
- Strong Performance in Health Care: Late Tuesday afternoon, the NYSE Health Care Index rose by 2%, indicating a rebound in investor confidence towards the health sector, likely driven by an overall improvement in market sentiment.
- Signs of Market Recovery: The rise in health care stocks reflects optimistic expectations for economic recovery, particularly post-pandemic, as demand for health services continues to grow, potentially boosting the performance of related companies.
- Increased Investor Attention: With the improved performance of the health care sector, investors may reassess their portfolios and increase allocations to health stocks, thereby driving further growth and stability in the industry.
- Optimistic Industry Outlook: The strong performance in the health sector could attract more capital inflows, especially in the fields of innovative drugs and medical technologies, which are expected to provide momentum for future growth.
See More
Agios Pharmaceuticals Accelerates FDA Approval for Mitapivat
- Accelerated FDA Approval: Agios Pharmaceuticals' recent meeting with the FDA has laid the groundwork for a proposal for a confirmatory clinical trial for mitapivat, with expectations to submit a request for accelerated full approval within the next few months, potentially expediting the drug's market entry for sickle cell disease treatment.
- Significant Market Potential: The sickle cell disease therapy market, currently valued at approximately $4 billion, is projected to grow to over $14 billion by 2034, with mitapivat poised to expand market size by providing a much-needed effective treatment option.
- Strong Clinical Trial Performance: Mitapivat has shown promising results in the RISE UP trials and is already approved for various forms of anemia, with the FDA's special regulatory consideration highlighting the urgent need for new therapies in the sickle cell disease space.
- Positive Investor Reaction: Following the FDA's recommendation for a simplified confirmatory trial, Agios shares surged by 21.7%, indicating strong market optimism regarding the drug's prospects, despite the company's ongoing losses, suggesting potential for further stock price appreciation for risk-tolerant investors.
See More
Agios Executive Sells Shares for Tax Obligation
- Executive Stock Sale: Viswanadhan Krishnan, Chief Corporate Development and Strategy Officer at Agios Pharmaceuticals, sold 2,959 shares on March 5, 2026, for approximately $82,000, triggered by the vesting of 8,100 restricted stock units (RSUs), reflecting standard practice for executives to manage tax obligations.
- Holding Analysis: Following the transaction, Krishnan's direct stock holdings decreased by 36.53%, yet he retains 16,200 unvested RSUs, indicating substantial potential exposure to Agios, which may convert to common stock in the future.
- Financial Overview: Agios reported $54 million in revenue for 2025, an 86% increase year-over-year, and ended the year with approximately $1.2 billion in cash, providing a solid financial runway to support its pipeline without immediate financing pressure.
- FDA Accelerated Approval Plans: Agios announced plans to pursue FDA accelerated approval for its lead product, PYRUKYND, in sickle cell disease, with a supplemental New Drug Application (sNDA) submission expected in the coming months, potentially opening significant market expansion opportunities for the company.
See More
Agios Pharmaceuticals' Mitapivat Gains FDA Attention for Sickle Cell Treatment
- FDA Accelerated Approval: Agios Pharmaceuticals' mitapivat has received FDA permission to conduct an abbreviated confirmatory clinical trial for sickle cell disease treatment, with plans to submit a request for accelerated approval in the coming months, potentially expediting the drug's market entry to meet urgent treatment needs.
- Positive Market Reaction: Following the FDA's recommendation, Agios' stock surged 21.7%, reflecting optimistic market expectations for the drug's potential, especially as the sickle cell disease treatment market is projected to grow from $4 billion annually to over $14 billion by 2034.
- Strong Clinical Trial Performance: Mitapivat has shown excellent results in the RISE UP trials and is already approved for various forms of anemia, indicating its potential as a multipurpose therapy that could provide more treatment options for patients and fill a significant market gap.
- Financial Health Concerns: Despite progress in drug development, Agios reported a loss of $413 million last year with only $54 million in revenue, prompting investors to carefully consider the company's financial stability and the potential for future market volatility.
See More
Agios Seeks Accelerated Approval for Mitapivat in Sickle Cell Disease
- FDA Review Progress: Agios has submitted a proposal for a confirmatory clinical trial to the FDA for Mitapivat, aimed at supporting its accelerated approval in sickle cell disease, indicating the company's proactive efforts to meet patient needs.
- Clinical Trial Results: The RISE UP Phase 3 trial demonstrated that Mitapivat significantly improved hemoglobin levels compared to placebo, although the annualized rate of pain crises did not reach statistical significance, reflecting the drug's potential clinical value.
- Future Plans: The company plans to submit a supplemental New Drug Application (sNDA) for Mitapivat in the coming months and is actively working with the FDA to align on the confirmatory trial, showcasing its strong commitment to expedited market entry.
- Market Impact: Sickle cell disease is a serious inherited blood disorder, and the successful launch of Mitapivat could provide new treatment options for patients, potentially significantly improving their quality of life and enhancing Agios's market position.
See More
Agios Pharmaceuticals Under Investigation Following Phase 3 Trial Results, Stock Plummets
- Investigation Launched: Levi & Korsinsky has initiated an investigation into Agios Pharmaceuticals, Inc. regarding potential violations of federal securities laws, indicating serious concerns about the company's compliance practices.
- Clinical Trial Results: On November 19, 2025, Agios reported that its RISE UP Phase 3 trial met one primary endpoint but failed to show statistically significant improvement in annualized pain crises, highlighting limitations in treatment efficacy.
- Stock Price Reaction: Following the trial results, Agios' stock plummeted by $22.33 to open at $23.16, reflecting a significant decline in market confidence regarding the company's future prospects, which may impact its ability to raise capital.
- Investor Impact: The investigation and stock drop could erode investor trust in Agios, further affecting its market performance and shareholder value, underscoring the company's inadequate risk management in clinical development.
See More
Health Care Stocks Rise 2% Boosting Market
- Strong Performance in Health Care: Late Tuesday afternoon, the NYSE Health Care Index rose by 2%, indicating a rebound in investor confidence towards the health sector, likely driven by an overall improvement in market sentiment.
- Signs of Market Recovery: The rise in health care stocks reflects optimistic expectations for economic recovery, particularly post-pandemic, as demand for health services continues to grow, potentially boosting the performance of related companies.
- Increased Investor Attention: With the improved performance of the health care sector, investors may reassess their portfolios and increase allocations to health stocks, thereby driving further growth and stability in the industry.
- Optimistic Industry Outlook: The strong performance in the health sector could attract more capital inflows, especially in the fields of innovative drugs and medical technologies, which are expected to provide momentum for future growth.
See More
Agios Pharmaceuticals Accelerates FDA Approval for Mitapivat
- Accelerated FDA Approval: Agios Pharmaceuticals' recent meeting with the FDA has laid the groundwork for a proposal for a confirmatory clinical trial for mitapivat, with expectations to submit a request for accelerated full approval within the next few months, potentially expediting the drug's market entry for sickle cell disease treatment.
- Significant Market Potential: The sickle cell disease therapy market, currently valued at approximately $4 billion, is projected to grow to over $14 billion by 2034, with mitapivat poised to expand market size by providing a much-needed effective treatment option.
- Strong Clinical Trial Performance: Mitapivat has shown promising results in the RISE UP trials and is already approved for various forms of anemia, with the FDA's special regulatory consideration highlighting the urgent need for new therapies in the sickle cell disease space.
- Positive Investor Reaction: Following the FDA's recommendation for a simplified confirmatory trial, Agios shares surged by 21.7%, indicating strong market optimism regarding the drug's prospects, despite the company's ongoing losses, suggesting potential for further stock price appreciation for risk-tolerant investors.
See More
Agios Executive Sells Shares for Tax Obligation
- Executive Stock Sale: Viswanadhan Krishnan, Chief Corporate Development and Strategy Officer at Agios Pharmaceuticals, sold 2,959 shares on March 5, 2026, for approximately $82,000, triggered by the vesting of 8,100 restricted stock units (RSUs), reflecting standard practice for executives to manage tax obligations.
- Holding Analysis: Following the transaction, Krishnan's direct stock holdings decreased by 36.53%, yet he retains 16,200 unvested RSUs, indicating substantial potential exposure to Agios, which may convert to common stock in the future.
- Financial Overview: Agios reported $54 million in revenue for 2025, an 86% increase year-over-year, and ended the year with approximately $1.2 billion in cash, providing a solid financial runway to support its pipeline without immediate financing pressure.
- FDA Accelerated Approval Plans: Agios announced plans to pursue FDA accelerated approval for its lead product, PYRUKYND, in sickle cell disease, with a supplemental New Drug Application (sNDA) submission expected in the coming months, potentially opening significant market expansion opportunities for the company.
See More
Agios Pharmaceuticals' Mitapivat Gains FDA Attention for Sickle Cell Treatment
- FDA Accelerated Approval: Agios Pharmaceuticals' mitapivat has received FDA permission to conduct an abbreviated confirmatory clinical trial for sickle cell disease treatment, with plans to submit a request for accelerated approval in the coming months, potentially expediting the drug's market entry to meet urgent treatment needs.
- Positive Market Reaction: Following the FDA's recommendation, Agios' stock surged 21.7%, reflecting optimistic market expectations for the drug's potential, especially as the sickle cell disease treatment market is projected to grow from $4 billion annually to over $14 billion by 2034.
- Strong Clinical Trial Performance: Mitapivat has shown excellent results in the RISE UP trials and is already approved for various forms of anemia, indicating its potential as a multipurpose therapy that could provide more treatment options for patients and fill a significant market gap.
- Financial Health Concerns: Despite progress in drug development, Agios reported a loss of $413 million last year with only $54 million in revenue, prompting investors to carefully consider the company's financial stability and the potential for future market volatility.
See More
